Business
Exicure, Inc. Reports Full Year 2019 Financial Results and Corporate Progress
- Friedreich’s ataxia chosen as first neurological indication - Reported Phase 1b data for lead immuno-oncology candidate in solid tumors -Development
About this update from Exicure, Inc.
[{"type":"text","content":"\n- Friedreich’s ataxia chosen as first neurological indication\n\n\n- Reported Phase 1b data for lead immuno-oncology candidate in solid tumors\n\n\n-Development partnership with Allergan in hair loss disorders\n\n\n- Cash and short-term investments on Dec. 31, 2019 of $110.8 million\n\n CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nExicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial results for year ended December 31, 2019 and provided an update on corporate progress.\n\n\n“2019 was a pivotal year for Exicure as we joined strong scientific and clinical progress with the capital resources and distinguished investors necessary to expand our pipeline and build our organization,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “Looking ahead, we intend to invest in growing a pipeline of drug candidates targeting neurological indications, as well as advance our Merkel cell and cutaneous squamous cell carcinoma programs into Phase 2 trials. We believe our ongoing clinical progress in immuno-oncology and dermatology has influenced our ability to expand our SNA platform in additional therapeutic areas through collaborative partnerships. Our collaboration with Allergan in hair loss disorders is just one of what we hope will be a number of such partnerships expanding our SNA platform into new therapeutic areas,” concluded Dr. Giljohann.\n\n\nCorporate Progress\n\n\nKey achievements for Exicure during 2019 include:\n\n\n\nEstablished Friedreich’s ataxia as Exicure’s first neurological indication, being developed in collaboration with the Friedreich’s Ataxia Research Alliance\n\n\nAnnounced preliminary data in the ongoing Phase 1b/2 trial of lead immuno-oncology candidate AST-008 in patients with solid tumors \n\n\nEntered a collaboration agreement with Allergan for two discovery programs in hair loss disorders with $25 million upfront and up to $725 million in potential milestones\n\n\nExpanded scientific advisory board to include neurology experts Dr. Susan Perlman and Dr. Hank Paulson\n\n\nExpanded Board of Directors with the addition of Jeffrey L. Cleland of Orpheris, Bali Muralidhar of Abingworth LLP, Bosun Hau of Tybourne Capital Management, and Tim Walbert of Horizon Therapeutics\n\n\nRaised appr...